SurModics bets on eye implant maker InnoRx
This article was originally published in Clinica
SurModics has invested some $17m in a cash and stock purchase of InnoRx, a Mobile, Alabama-based firm that is developing an implant for the delivery of drugs to the eye. Eden Prairie, Minnesota-based SurModics, which already had a minority stake in InnoRx and has collaborated with the firm for three years, paid $4.1m in cash and issued about 0.6m shares to acquire the remaining shares. InnoRx's shareholders stand to receive another 0.6m SurModics shares if the company's product receives FDA approval and meets certain revenue targets.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.